BIOTRONIK
286 articles about BIOTRONIK
-
BIOTRONIK and IMDS Join Forces to Launch Innovative Micro Rx Catheter
2/8/2024
BIOTRONIK is proud to introduce the Micro Rx™ catheter, a novel rapid exchange microcatheter developed to easily enhance guidewire support during percutaneous coronary interventions.
-
BIOTRONIK's DX Technology Reaches Significant Milestone: 100,000 DX Devices Implanted
1/29/2024
BIOTRONIK announced the milestone achievement of 100,000 implanted single lead implantable cardioverter-defibrillators equipped with DX Technology enabling direct atrial sensing for atrial fibrillation detection and monitoring.
-
BIOTRONIK Receives FDA Approval For Next-Generation Family of Pacemakers
7/6/2023
BIOTRONIK today announced U.S. Food and Drug Administration (FDA) approval of its portfolio of Amvia Edge pacemakers and cardiac resynchronization therapy pacemaker (CRT-P).
-
BIOTRONIK Demonstrates Ongoing Commitment to Advancing Scientific Knowledge at HRS
6/23/2023
Continuing a history of commitment to furthering research in its field, four studies supported by BIOTRONIK's real-world evidence generating research initiative, CERTITUDE, were presented at Heart Rhythm 2023 on May 20th and 21st.
-
BIOTRONIK Enrolls First Patient Into BIO-CONDUCT, First IDE Trial to Study Use of Stylet-Driven Leads for Conduction System Pacing
12/13/2022
BIOTRONIK, a global leader in the treatment of cardiac and vascular disease is pleased to announce the first patient enrollment in BIO-CONDUCT, an FDA approved investigational device exemption (IDE) trial examining the use of the BIOTRONIK Solia S pacing lead when implanted in the left bundle branch (LBB) area, a location for which the Solia S lead is not currently approved.
-
BIOTRONIK, Inc. Reaches Settlement with U.S. Department of Justice
7/22/2022
BIOTRONIK, Inc. announced today that it has entered into a civil settlement with the U.S. Department of Justice, the U.S. Attorney's Office for the Central District of California, and the U.S. Department of Health and Human Services, Office of Inspector General, to resolve historical claims of alleged overuse of paid consultants to train field personnel and limited instances of excessive customer meals and travel.
-
Latest Study Shows New Algorithm Can Predict Heart Failure Hospitalizations
8/18/2021
BIOTRONIK announced the results from a new study published in EUROPACE this week confirming that heart failure decompensation can be predicted early when monitored using an algorithm that combines existing remote monitoring trends and baseline risk stratification.
-
BIOTRONIK's Implantable Cardiac Monitor Receives Prestigious Industry Award
7/28/2021
In association with Heart Rhythm 2021, BIOTRONIK announced that the latest implantable cardiac monitor, BIOMONITOR IIIm, has been recognized by internationally-renowned research analysts Frost & Sullivan as high-performing across a range of innovation and customer value criteria.
-
Life science jobs are booming in several regions around the U.S. One is the Pacific Northwest, specifically Oregon; another is the Philadelphia area. Here’s a look.
-
FDA Clears Fever-Detecting Vital Data Sensor in New Cardiac Monitor
12/16/2020
BIOTRONIK today announced FDA clearance and availability of the Vital Data Sensor, which identifies body temperature increases potentially associated with fever, in the new BIOMONITOR IIIm injectable cardiac monitor (ICM), as shown in a published case report 1 .
-
New Alliance Maps the Way in Electrophysiology
5/20/2020
A New Strategic Alliance Between BIOTRONIK, A Leader In Cardiac Rhythm Management, and Acutus Medical, Electrophysiology Innovator, Expected to Offer More Efficient and Effective Diagnosis and Treatment for Arrhythmia Patients [20-May-2020] CARLSBAD, Calif. and BERLIN , May 20, 2020 /PRNewswire/ -- Acutus Medical and BIOTRONIK today announced a new alliance to p
-
BIOTRONIK's Ultrathin Strut Orsiro Coronary Drug-Eluting Stent Continues to Deliver Excellent Results After Three Years
2/24/2020
Data from BIOFLOW-V Trial Presented at CRT and Published in JACC: Cardiovascular Interventions Reinforces Orsiro's Ability to Outperform Abbott's Xience
-
BIOTRONIK, Inc. Appoints David Hayes, MD, as Chief Medical Officer
1/27/2020
BIOTRONIK, Inc. today announced the appointment of David Hayes, MD, FACC, as Chief Medical Officer
-
Prix Galien Selects BIOTRONIK's PK Papyrus Covered Coronary Stent as Award Finalist
7/31/2019
PK Papyrus Stent Delivers Emergency Treatment for Acute Coronary Artery Perforations
-
BIOTRONIK Receives FDA Clearance on Next-Gen Injectable Cardiac Monitor: BIOMONITOR III
7/8/2019
BIOTRONIK today announced FDA clearance of the BIOMONITOR III injectable cardiac monitor (ICM). BIOMONITOR III is designed to document suspected arrhythmia or unexplained syncope with increased clarity, enabling fast diagnosis and appropriate treatment.
-
Late-Breaking Data at EuroPCR: BIOTRONIK's Orsiro Demonstrates Unique Benefits in Small Vessels
5/21/2019
A Subgroup Analysis of the BIO-RESORT RCT Three-Year Data Showed Significant Differences in Efficacy in Favor of Ultrathin Strut Orsiro [21-May-2019] PARIS and BUELACH, Switzerland , May 21, 2019 /PRNewswire/ -- Focusing on patients with small vessels, three-year outcomes of the BIO-RESORT randomized controlled trial (RCT) showed a significantly lower target lesion re
-
Focusing on Women: BIOTRONIK Launches Study to Understand the Impact of ICDs in NICM Patients
5/6/2019
BIO-LIBRA Study Aims to Break the Tradition of Underrepresentation of Women in Heart Disease Studies
-
US Physicians Now Treating Patients with BIOTRONIK's Ultraslim Acticor DX Devices
4/29/2019
New Hybrid ICDs Feature Increased Longevity, Smooth BIOshape and Simplified DF4 Header Configuration
-
BIOTRONIK Launches PK Papyrus Covered Coronary Stent in the US
4/10/2019
Lifesaving Solution Now Available Nationwide for Treatment of Acute Coronary Artery Perforations
-
InfoBionic Signs BIOTRONIK as Exclusive U.S. Distributor for MoMe® Kardia
8/28/2018
InfoBionic today announced an exclusive, strategic agreement with medical device manufacturer BIOTRONIK for U.S. distribution of InfoBionic’s proprietary MoMe® Kardia system, effective immediately.